SCHEMBL6034858

SCHEMBL6034858

CCCc1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCCOc1cc(CCC(=O)O)n(-c2ccccc2)n1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GCGR P47871 3/20 0.36
LTB4R Q15722 3/20 0.35
MAPT P10636 2/20 0.34
PPARD Q03181 4/20 0.34
PPARA Q07869 2/20 0.34
LIPE Q05469 1/20 0.33
LTB4R2 Q9NPC1 1/20 0.33
GCG P01275 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
HDAC4 P56524 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
HPGD P15428 1/20 0.33
S100A4 P26447 1/20 0.32
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035370 0.98 GCGR (0.37) GCGRLTB4RMAPTPPARDPPARA
SCHEMBL6035755 0.90 GCGR (0.37) GCGRLTB4RMAPTPPARDPPARA
SCHEMBL6035372 0.89 PPARD (0.36) GCGRLTB4RMAPTPPARDPPARA
SCHEMBL6036236 0.88 MLYCD (0.35) GCGRLTB4RPPARDPPARAGCG
SCHEMBL6035943 0.88 GCGR (0.38) GCGRLTB4RMAPTPPARDPPARA
SCHEMBL6034689 0.88 PPARD (0.36) GCGRLTB4RMAPTPPARDPPARA
SCHEMBL1633424 0.87 SMN1; SMN2 (0.37) GCGRLTB4RMAPTPPARDPPARA
SCHEMBL6036323 0.86 LTB4R (0.38) GCGRLTB4RPPARDPPARAKDM4E
SCHEMBL6035849 0.85 MLYCD (0.36) GCGRLTB4RPPARDPPARAGCG
SCHEMBL6035388 0.85 SMN1; SMN2 (0.37) GCGRMAPTPPARDPPARAGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 GCGR 93/4885LTB4R 1376/4885MAPT 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.